No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The CD33 Targeted Immunotherapeutic market is a subset of the Oncology Drugs market, focusing on treatments that target the CD33 antigen. These treatments are designed to stimulate the body's immune system to recognize and attack cancer cells. CD33 Targeted Immunotherapeutics are used to treat a variety of hematological malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). These treatments are typically administered intravenously and can be used in combination with other therapies.
Companies in the CD33 Targeted Immunotherapeutic market include Celgene Corporation, AbbVie, Inc., and Novartis AG. Other companies in the market include Bristol-Myers Squibb, Merck & Co., Inc., and Pfizer, Inc. Show Less Read more
